Roche Holding AG (RHHBY.PK) said its first-quarter group sales rose 2% at constant exchange rates to 11.03 billion Swiss francs from a year ago. Excluding Tamiflu, sales growth is 3%. Sales were down 1% in Swiss francs, while it was up 1% in US dollars.
Roche also confirmed its full-year outlook for 2012. Barring unforeseen events, Roche still expects low to mid-single-digit sales growth at constant exchange rates for the Group and the Pharmaceuticals Division in 2012.
Despite a challenging market environment, based on the expected sales growth and continued efficiency improvements, Roche continues to aim for a high single-digit increase in Core Earnings per Share at constant exchange rates.
Click here to receive FREE breaking news email alerts for Roche Holding AG and others in your portfolio
by RTT Staff Writer
For comments and feedback: email@example.com